Ascendis Pharma AS (ASND) Upgraded to “Buy” at Zacks Investment Research
Ascendis Pharma AS (NASDAQ:ASND) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm currently has a $22.00 price target on the stock. Zacks Investment Research’s price objective indicates a potential upside of 10.50% from the stock’s current price.
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
A number of other research firms have also recently issued reports on ASND. TheStreet raised shares of Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Leerink Swann reaffirmed a “buy” rating on shares of Ascendis Pharma AS in a research report on Friday, September 2nd. Finally, Wedbush assumed coverage on shares of Ascendis Pharma AS in a research report on Monday, September 26th. They issued an “outperform” rating and a $34.00 price target on the stock.
Shares of Ascendis Pharma AS (NASDAQ:ASND) traded up 0.40% during midday trading on Tuesday, hitting $19.99. The stock had a trading volume of 11,967 shares. The company’s market cap is $503.61 million. The stock’s 50-day moving average price is $19.16 and its 200 day moving average price is $16.12. Ascendis Pharma AS has a 52 week low of $11.92 and a 52 week high of $21.70.
Ascendis Pharma AS (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.10. On average, equities analysts forecast that Ascendis Pharma AS will post ($3.14) earnings per share for the current year.
Ascendis Pharma AS Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related stocks with our FREE daily email newsletter.